$2.04
-0.10-4.67%
Last update: Oct 30, 7:12 PM
Altimmune Inc (ALT) Stock Price, Quote, News & History
ALTNASDAQ
Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.
You can purchase shares of Altimmune (NASDAQ:ALT) through any online brokerage.
Other companies in Altimmune’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Altimmune has a consensus price target of $17.00.
The stock price for Altimmune (NASDAQ: ALT) is $2.07 last updated October 30, 2026 at 7:12 PM EDT.
There are no upcoming dividends for Altimmune.
Altimmune does not have any upcoming earnings scheduled.
There is no upcoming split for Altimmune.
Altimmune is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a...
